Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Catholic University, Italy
• Treatments: Formoterol Fumarate

Criteria

Inclusion Criteria:

• Mild to moderate asthma

• Stable clinical conditions

Exclusion Criteria:

• Smokers

• Current therapy with oral steroids

• Exacerbations within the past 3 months